These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 8495620

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats.
    McCaleb ML, McKean ML, Hohman TC, Laver N, Robison WG.
    Diabetologia; 1991 Oct; 34(10):695-701. PubMed ID: 1959701
    [Abstract] [Full Text] [Related]

  • 4. Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion.
    McAuliffe AV, Brooks BA, Fisher EJ, Molyneaux LM, Yue DK.
    Nephron; 1998 Nov; 80(3):277-84. PubMed ID: 9807036
    [Abstract] [Full Text] [Related]

  • 5. Prevention of urinary albumin excretion in 6 month streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat.
    McCaleb ML, Sredy J, Millen J, Ackerman DM, Dvornik D.
    J Diabet Complications; 1988 Nov; 2(1):16-8. PubMed ID: 2968349
    [Abstract] [Full Text] [Related]

  • 6. Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition.
    Pedersen MM, Christiansen JS, Mogensen CE.
    Diabetes; 1991 May; 40(5):527-31. PubMed ID: 1902426
    [Abstract] [Full Text] [Related]

  • 7. Prevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic rat.
    Donnelly SM, Zhou XP, Huang JT, Whiteside CI.
    Biochem Cell Biol; 1996 May; 74(3):355-62. PubMed ID: 8883841
    [Abstract] [Full Text] [Related]

  • 8. The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus.
    Chang WP, Dimitriadis E, Allen T, Dunlop ME, Cooper M, Larkins RG.
    Diabetologia; 1991 Apr; 34(4):225-31. PubMed ID: 1906023
    [Abstract] [Full Text] [Related]

  • 9. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors.
    Tilton RG, Chang K, Pugliese G, Eades DM, Province MA, Sherman WR, Kilo C, Williamson JR.
    Diabetes; 1989 Oct; 38(10):1258-70. PubMed ID: 2507378
    [Abstract] [Full Text] [Related]

  • 10. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients.
    Rossing P, Hommel E, Smidt UM, Parving HH.
    Diabetes; 1993 May; 42(5):715-9. PubMed ID: 8482428
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.
    Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving HH.
    Diabetes; 1997 Mar; 46(3):481-7. PubMed ID: 9032106
    [Abstract] [Full Text] [Related]

  • 18. Early glomerular hyperfiltration and the development of late nephropathy in type 1 (insulin-dependent) diabetes mellitus.
    Lervang HH, Jensen S, Brøchner-Mortensen J, Ditzel J.
    Diabetologia; 1988 Oct; 31(10):723-9. PubMed ID: 3071482
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.